Publications:​

  • Golombick T, Diamond T, Manoharan A, Ramakrishna R and Badmaev V. Effect of the ginger derivative, 6-shogaol, on ferritin levels in patients with low to int-1-risk myelodyplasia - a small investigative study. Clinical medicine insights. 2017;10:1-4. DOI:10.1177/1179545X17738755

  • Ooi SL, McMullen D, Golombick T, Pak SC. Evidence-based review of Biobran/MGN-3 arabinoxylan compound as a complementary therapy for conventional cancer treatment. Integrative Cancer Therapies. 2017: 1-14. DOI:10.1177/1534735417735379

  •  Golombick T, Diamond T, Manoharan A and Ramakrishna R. Long-term follow-up of curcumin treated MGUS/SMM patients - an updated single centre experience. Hematol Med Oncol. 2017;2(2):1-2. DOI:10.15761/HMO1000125.

  • Golombick T, Diamond T, Manoharan A and Ramakrishna R. Addition of rice bran arabinoxylan to curcumin therapy may be of benefit to patients with early stage B-cell lymphoid malignancies [Monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM) or stage 0/1 chronic lymphocytic leukemia (CLL)] – a preliminary clinical study. Integrative Cancer Therapies. 2016:1-7; DOI:10.1177/1534735416635742.

  • Golombick T, Diamond T, Manoharan A and Ramakrishna R. B-cell disorders and curcumin. Integrative Cancer Therapies. 2015; DOI: 10.1177/1534735415622013.

  • Golombick T, Diamond T, Manoharan A and Ramakrishna R. The Effect of Curcumin (as Meriva) on Absolute Lymphocyte Count (ALC), NK Cells and T Cell Populations in Patients with Stage 0/1 Chronic Lymphocytic Leukemia. Journal of Cancer Therapy,2015;6:566-571

  • Golombick T, Diamond T, Manoharan A and Ramakrishna R.Stabilisation of laryngeal AL amyloidosis with long term curcumin therapy – a case report. Case Reports in Hematology.Volume 2015, Article ID 910528. DOI 10.1155/2015/910528.

  • Wong R, Golombick T, Diamond T, Manoharan A and Ramakrishna R. Curcumin enhances the cytotoxic and chemo-sensitising effects of lenalidomide in human multiple myeloma cells. J Hematological Malignancies, 2013,Vol 3, no 2,1-7.

  • Golombick T, Diamond T, Manoharan A and Ramakrishna R. Long term use of curcumin in two smoldering multiple myeloma patients. J Hematological Malignancies, 2013, Vol 3, no 1, 18-23.

  • Golombick T, Diamond T, Manoharan A and Ramakrishna R. Response to Vermorken et al – curcumin and free light chains.Am J Hematol 2012;87:E80-E81. DOI:10.1002/ajh.23294.

  • Golombick T, Diamond T, Manoharan A and Ramakrishna R. Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) and Curcumin: A Randomised, Double-blind Placebo-Controlled Cross-over 4g study and an Open-label 8g Extension Study. American J Hematology. 2012;87:455-460

  • Diamond T, Golombick T, et al. The impact of osteoporosis (as measured by lumbar spine quantitative computed tomography) on disease activity and survival in myeloma patients: A 13-year prospective study. Am J Hematol 2011, DOI:10.1002/ajh.22030

  • Diamond T, Golombick T, Manoharan A. Vitamin D status may effect the skeletal complications of multiple myeloma. American Journal of Haematology 2010;85(4) 302-303.

  • Golombick T, Diamond T, Badmaev et al. The potential role of curcumin in patients with monoclonal gammopathy of undefined significance – its effect on paraproteinemia and the urinary N-telopeptide of type 1 collagen bone turnover marker. Clin Cancer Res 2009;15(18) 5917-5922.Golombick T and Diamond T. Prevalence of MGUS/Myeloma in Patients with Acute           Osteoporotic Vertebral Fractures. Acta Haematol 2008;120:87-90 (DOI: 10.1159/000162282

 

Conference Presentations: 

2007

  • Diamond T, Golombick T. Prevalence of MGUS/Myeloma in Patients Presenting with Acute Osteoporotic Vertebral Fractures over 18 Months. HAA 2007 (HSANZ/ANZSBT/ASTH 2007 ASM), Surfers Paradise, Queensland. 

2008 

  • Golombick T, Diamond T, Badmaev V. The potential role of curcumin in plasma cell dyscrasia/paraproteinemia. 2nd International Symposium on Translational Research. Mumbai, India. 

2009 

  • Diamond T, Golombick T. Severity of osteoporosis in multiple myeloma and the prognostic role of lumbar spine QCT. Haematological Society of ANZ Annual Meeting, Adelaide, Australia. 

  • Golombick T, Diamond T. The Potential Role of Curcumin in Patients with Monoclonal Gammopathy of Undefined Significance- Its Effect on Paraprotein and the Urinary N-Telopeptide of Type 1 Collagen Bone Turnover Marker. Haematological Society of ANZ Annual Meeting, Adelaide, Australia. 

2010

  • Golombick T, Diamond T. Role of Curcumin in Patients with Monoclonal Gammopathy of Undefined Significance. Annual Meeting of IBMS, Cancer and Bone, Sydney, Australia. 

  • Diamond T, Golombick T, Manoharan A. Vitamin D status may effect skeletal complications of multiple myeloma. St George Hospital Annual Symposium, Sydney, Australia (Award: First Prize). 

  • Diamond T, Golombick T, Manoharan A. Vitamin D status may effect skeletal complications of multiple myeloma. NHMRC Research Forum. Vitamin D Workshop. Melbourne. 

2011 

  • Golombick T, Diamond T, Manoharan A and Ramakrishna R. Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) and Curcumin: A Randomised, Double-blind Placebo-Controlled Cross-over 4g study and an Open-label 8g Extension Study. Eighth International Conference of the Society for Integrative Oncology. Cleveland, Ohio, USA. Award Session. 

  • Golombick T, Diamond T, Manoharan A and Ramakrishna R. Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) and Curcumin: A Randomised, Double-blind Placebo-Controlled Cross-over 4g study and an Open-label 8g Extension Study. Nutrition in Medicine Conference (1). Swiss Grand Hotel, Bondi Beach, Sydney, Australia. 

  • Diamond T, Golombick T and Wong Y. The effect of oral cholecalciferol 2000 IU versus 5000 IU on serum vitamin D, PTH, bone and muscle strength in patients with vitamin D deficiency. ANZ Bone Mineral Society Annual Scientific Meeting, Gold Coast, Australia. 

2013 

  • Golombick T, Diamond T, Manoharan A and Ramakrishna R. Multiple Myeloma Precursor Disease and Curcumin. Fourteenth International Myeloma Workshop, April 3-7, 2013, Kyoto, Japan 

  • Golombick T, Wong R, Diamond T, Manoharan A and Ramakrishna R. Curcumin Enhances the Cytotoxic and Chemosensitising Effects of Lenalidomide in Human Multiple Myeloma Cells. Fourteenth International Myeloma Workshop, April 3-7, 2013, Kyoto, Japan 

2016 

  • Golombick T, Diamond T, Manoharan A and Ramakrishna R. The benefit of Curcumin in patients with early stage B cell lymphoid malignancies (MGUS, SMM OR STAGE 0/1 CLL). Nutrition in Medicine Conference, April 30 – May 1, Sofitel Wentworth

Publications and conference presentations 

Disclaimer

The information contained in this site is intended to provide helpful health information. While the site managers have exercised due care in ensuring the accuracy of the material contained on this website, the information is made available on the understanding that the site managers are not providing professional advice on a particular matter. Nothing contained in this site is intended to be used as medical advice and it is not intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for your own health professional's advice. Before relying on the material in any important matter, users should carefully evaluate its accuracy, currency, completeness and relevance for their purposes, and should obtain any appropriate professional advice relevant to their particular circumstances. In some cases the material may incorporate or summarise views, guidelines or recommendations of third parties. Such material is assembled in good faith, but does not necessarily reflect the considered views of the site managers, or indicate a commitment to a particular course of action. The site managers do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information provided on this website.

Watch and Wait Blood Cancers

Watch and Wait Blood Cancers